2invest AG
SYGNIS AG announces publication in ‘Nature Communications’ of the TruePrime(TM) novel method for whole genome amplification
DGAP-News: SYGNIS AG / Key word(s): Scientific publication Press Release SYGNIS AG announces publication in “Nature Communications” of the TruePrimeTM novel method for whole genome amplification – TruePrimeTM promises to facilitate and improve single cell genomic analysis – TruePrimeTM is based on PrimPol, one of the most innovative discoveries – Nature Communications is a worldwide reference publication for researchers
The article discusses the novel TruePrime(TM) method, which facilitates and improves on single cell analysis by reducing bias and errors with other clear advantages when compared to current gold standard DNA isothermal amplification methods. Nature Communications is one of the most important references for researchers. As part of the publication process, the article is peer reviewed by world renowned opinion leaders. This review process validates SYGNIS’ science and technology and enables the publication to have a significant impact in the scientific community, and can become an efficient marketing tool to promote new technologies. Dr. Heikki Lanckriet, Co-CEO and CSO of SYGNIS, said: “Publication in Nature Communications is another key milestone achievement for us that will help to promote and validate our new technology, TruePrime(TM). TruePrime(TM) is one of the most innovative discoveries in the molecular biology field and one of the key products in SYGNIS’ portfolio. This is proof of a growing awareness and interest in the scientific community for the importance of the combination of TthPrimPol’s unique ability to synthesize DNA-primers with the highly processive Phi29 DNA polymerase to enable near complete whole genome amplification from single cells. The research and discovery SYGNIS undertook with Professor Luis Blanco’s laboratory at Centro de Biología Molecular Severo Ochoa (CSIC-UAM) in Madrid, to discover PrimPol and afterwards to develop TruePrime(TM) is truly a paradigm shift for DNA or RNA amplification. We are very optimistic about the response that the scientific community will have after the publication of this article. As a result, we expect to have an important increase in the demand of TruePrime(TM) products. This article is part of our marketing strategy to promote and validate our most important technologies through leading worldwide scientific journals.” In July this year SYGNIS launched the TruePrime(TM) Single Cell WGA Kit V2 with significantly improved conditions for an expanded range of cell types and applications. Abstract published in Nature Communications: displacement amplification (MDA) method based in the unique DNA primase features of Thermus thermophilus (Tth) PrimPol. TthPrimPol displays a potent primase activity preferring dNTPs as substrates unlike conventional primases. A combination of TthPrimPol’s unique ability to synthesize DNA-primers with the highly processive Phi29 DNA polymerase (Φ29DNApol) enables near complete whole genome amplification from single cells. This novel method demonstrates superior breadth and evenness of genome coverage, high reproducibility, excellent single nucleotide variant (SNV) detection rates with low allelic dropout (ADO) and low chimera formation as exemplified by sequencing Hek293 cells. Moreover, copy number variant (CNV) calling yields superior results compared to random primer-based MDA methods. The advantages of this method, that we named TruePrime(TM), promise to facilitate and improve single cell genomic analysis.” For further information, please contact:
About SYGNIS AG: www.sygnis.com SYGNIS AG is specialized in the development and the commercialization of proprietary technologies and offers a wide range of different commercial products addressing key challenges in molecular biology. With the acquisition of Expedeon Holdings, Ltd. based in Cambridge, UK, SYGNIS has added a complementary proteomic product portfolio. Resulting from this significant expansion, SYGNIS’ product portfolio now covers the entire workflow of molecular biology. The products are sold through a direct sales force and several distribution partners in Europe, the US and Asia. SYGNIS AG has offices in Germany, Spain and the UK, production sites in the UK and the US as well as sales offices in Asia. The company is listed on the German Stock Exchange in Frankfurt in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03). ### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###
2016-11-29 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English | |
Company: | SYGNIS AG | |
Waldhofer Str. 104 | ||
69123 Heidelberg | ||
Germany | ||
Phone: | +49 (0) 6221 3540 125 | |
Fax: | +49 (0) 6221 3540 127 | |
E-mail: | investors@sygnis.com | |
Internet: | www.sygnis.com | |
ISIN: | DE000A1RFM03 | |
WKN: | A1RFM0 | |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange | |
End of News | DGAP News Service |